Showing 6801-6810 of 8649 results for "".
- Lineage Cell Therapeutics to Host Expert Call Following OpRegen Data Update at 2020 AAO Meetinghttps://modernod.com/news/lineage-cell-therapeutics-to-host-expert-call-following-opregen-data-update-at-2020-aao-meeting/2478483/Lineage Cell Therapeutics will be hosting a call to discuss updated interim results from the phase 1/2a study of its lead product candidate, OpRegen, with one of the study’s principal investigators. OpRegen is a retinal pigment epithelium (RPE) cell transplant therapy currently in development for
- Prevent Blindness Encourages Everyone to Take a Screen Time-Outhttps://modernod.com/news/prevent-blindness-encourages-everyone-to-take-a-screen-time-out/2478441/In response to increased virtual activity during the coronavirus pandemic, Prevent Blindness launched
- Outpatient Visits Rebound for Most Specialties to Pre-COVID Levelshttps://modernod.com/news/outpatient-visits-rebound-for-most-specialties-to-pre-covid-levels/2478438/After taking a nosedive during the initial wave of the COVID-19 pandemic, then rising and plateauing, weekly outpatient visits in the United States have rebounded and now slightly exceed levels seen in late February, according to new data, Medscape
- Members of Congress Urge Leaders to Act to Protect Patient Access to Surgical Care and Stop Medicare Cutshttps://modernod.com/news/members-of-congress-urge-leaders-to-act-to-protect-patient-access-to-surgical-care-and-stop-medicare-cuts/2478433/A group of 229 Representatives sent a letter
- Coherent Ships 5,000th OEM ExciStar Devicehttps://modernod.com/news/coherent-ships-5000th-oem-excistar-device/2478427/Coherent recently delivered the 5,000th OEM ExciStar laser for refractive corneal surgery. “The longevity of the laser components and the excellent pulse stability at the ultra-short 193 nm laser wavelength have made the ExciStar family the ideal ablation source for ever faster and m
- Lilly, Incyte’s Olumiant Shows “Significant Effect” on COVID-19 Recovery Timeshttps://modernod.com/news/lilly-incytes-olumiant-shows-significant-effect-on-covid-19-recovery-times/2478401/Eli Lilly and Incyte shared more details, including mortality data, from the ongoing ACTT 2 trial evaluating their JAK1/JAK2 inhibitor Olumiant (baricitinib) in combination with Gilead Sciences’ Veklury (remdesivir) in patients with COVID-19 infection. The companies said last month that the
- CooperVision Presents 6-Year Data from MiSight 1 Day Studyhttps://modernod.com/news/coopervision-presents-6-year-data-from-misight-1-day-study/2478397/CooperVision is reporting the latest findings from its landmark MiSight 1 day clinical study, providing new insights about myopia management and the efficacy of the specially designed contact lens. Among many powerful outcomes are that nearly one in four children’s eyes originally fit with MiSigh
- Tarsus Releases Data from Io and Europa Trials for TP-03 to Treat Demodex Blepharitis and Begins Phase 2b/3 Saturn-1 Trialhttps://modernod.com/news/tarsus-releases-data-from-io-and-europa-trials-for-tp-03-to-treat-demodex-blepharitis-and-begins-phase-2b-3-saturn-1-trial/2478374/Tarsus Pharmaceuticals announced data from its phase 2 trials, Io (a Phase 2a, single-arm open-label trial) and Europa (a Phase 2b, randomized vehicle-controlled trial), evaluating the safety and efficacy of TP-03, a novel ophthalmic therapeutic being developed for t
- iSTAR Medical Reports Positive 6-Month Data for MINIject Devicehttps://modernod.com/news/istar-medical-reports-positive-6-month-data-for-miniject-device/2478354/iSTAR Medical announced that its microinvasive glaucoma surgery (MIGS) device MINIject showed consistently positive safety and efficacy outcomes in a larger patient population from ongoing trials. The pooled analysis reviewed data from over 130 patients implanted with MINIject into the supracilia
- Johnson & Johnson Starts Phase 3 Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/johnson-johnson-starts-phase-3-study-of-covid-19-vaccine-candidate/2478315/Johnson & Johnson launched a late-stage study of its COVID-19 vaccine candidate JNJ-78436735 following positive interim results from a phase 1/2a trial. The ENSEMBLE study will enroll up to 60,000 volunteers and will evaluate the safety and efficacy of a single vaccine dose versus placebo in